The use of Positron Emission Tomography scanning in occult and recurrent head and neck cancer

Acta Oto-Laryngologica, Supplement

Volumn , Issue 534, 1998, Pages 1-11

  Manolidis, Spiros ^a   Donald, Paul J ^b   Volk, Peter ^c   Pounds, Thomas R ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Northern California PET Imaging Ctr   (United States)

Author keywords

Distant metastases; Head and neck cancer; Local disease; PET scan; Positron emission tomography; Regional disease; Sensitivity; Specificity

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HEAD AND NECK CANCER; HUMAN; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEAD AND NECK TUMOR; LYMPH NODE METASTASIS; PATHOLOGY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031596432     PISSN: 03655237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. 18F fluorodeoxyglucose and Poistron Emission Tomography. Neurology 1982; 32: 1323-9.
2. Glaspy JA, Hawkins R, Hoh CK, et al. Use of Poistron Emission Tomography in oncology. Oncology 1993; 7: 41-6.
3. 13N-ammonia by human tumors as studies by Poistron Emission Tomography. Br J Radiol 1982; 55: 797-804.
4. 15O and Poistron Emission Tomography: analytical techniques and preliminary results. Neuroradiology 1982; 23: 63-74.
5. Beaney RP, Lammertsma AA, Jones T, et al. Poistron Emission Tomography for in vivo measurement of regional blood flow, oxygen utilization, and blood volume in patients with breast carcinoma. Lancet 1984; i: 131-4.
6. 11C) methionine for measuring in vivo protein synthesis rates with PET. J Nucl Med 1988; 29: 1419-27.
7. 11C) leucine and PET: methods, model and results in animals and humans. J Cereb Blood Flow Metab 1982; 9: 446-50.
8. Gelbard AS, Benua RS, Laughlin JS, et al. Quantitative scanning of ostegenic sarcoma with nitrogen-13-labeled L-glutamate. J Nucl Med 1979; 20: 782-4.
9. Reiman RE, Rosen G, Gelbard AS, et al. Imaging of primary ewing sarcoma with N-13 L-glutamate. Radiology 1982; 142: 494-500.
10. Yen CK, Budinger TF, Friedland RP, et al. Brain tumor evaluation using Rb-82 and Poistron Emission Tomography. J Nucl Med 1982; 23: 532-7.
11. 68Ga EDTA and positron emission computed tomography. J Cereb Blood Flow Metab 1984; 4: 504-15.
12. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988; 169: 45-8.
13. 124Iodine in patients with breast cancer. Int J Cancer 1991; 47: 344-7.
14. 18F-fluoro-2′deoxyuridine (FUdR) as a tracer of nucleic acid metabolism in brain tumors. J Neurosurg 1990; 72: 110-3.
15. Yang D, Emran A, Tansey W, et al. Radiosynthesis of florotamoxifen analogs. J Nucl Med 1990;31:903 (abstract).
16. Rasey JS, Koh W, Grierson ???, et al. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-992.
17. Lindholm P, Leskinen-Kallio S, Minn H, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J Nucl Med 1993; 34: 1711-6.
18. Warburg O. The Metabolism of Tumors. New York: Richard R Smith Inc., 1931: 129-69.
19. Hawkins R, Hoh CK, Glaspy JA, et al. Poistron Emission Tomography scanning in cancer. Cancer Invest 1994; 12: 74-87.
20. Fischman A, Alpert NM. FDG-PET in Oncology: There's More to It Than Looking at Pictures. J Nucl Med 1993;34:6-11 (editorial).
21. 14C-deoxyglucose methodfor the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897-916.
22. Phelps ME, Huang SC, Hoffman EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with F-18-2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6: 371-88.
23. 18F-fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979; 44: 127-37.
24. Huang SC, Phelps ME, Hoffman EJ, et al. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980; 238: E69-82.
25. Di Chiro D, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. Am J Radiol 1988; 150: 189-97.
26. Di Chiro D, Brooks RA. PET-FDG of untreated and treated cerebral gliomas. J Nucl Med 1988; 29: 421-2.
27. Alavi JB, Alavi A, Chawluk J, et al. Poistron Emission Tomography in patients with glioma: a predictor of prognosis. Cancer 1988; 62: 1074-8.
28. 18F)fluoro-D-glucose. N Engl J Med 1991;324:200 (letter).
29. Wahl RL, Cody R, Hutchins G, et al. Serial quantitative FDG/PET assessment of the metabolic responce of breast carcinomas to chemohormonotherapy. J Nucl Med 1990;31:746 (abstract).
30. Kubota K, Matsuzawa T, Fujuwara T, et al. Differential diagnosis of lung tumor with Poistron Emission Tomography: a prospective study. J Nucl Med 1990; 31: 1927-33.
31. 11C)L-methionine. J Comput Assist Tomogr 1988; 12: 794-6.
32. Abe Y, Matsuzawa T, Fujuwara T, et al. Clinical assessment of the therapeutic effects on cancer, 18F-2-deoxy-D-glucose and Poistron Emission Tomography: preliminary study of lung cancer. Int J Radiat Oncol Biol Phys 1990; 19: 1005-10.
33. Strauss LG, Clorius JH, Schlag P, et al. Reccurence of colorectal tumors: PET evaluation. Radiology 1989; 170:329-32.
34. Haberkom U, Strauss L, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with reccurent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32: 1485-90.
35. Strauss L, Tilgen W, Dimitrakopoulou A, et al. PET Studies with F-18-deoxyglucose (FDG) in Patients with Metastatic Melanoma Prior to and After Therapy. J Nucl Med 1990;31:804 (abstract).
36. Bailet JW, Abemayor E, Bradley AJ, et al. Poistron Emission Tomography: a new, precise, imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992; 102: 281-8.
37. Bailet JW, Sercarz JA, Abemayor E, et al. The use of Poistron Emission Tomography for early detection of reccurent head and neck squamou cell carcinoma in postradiotherapy patients. Laryngoscope 1995; 105: 135-9.
38. Chaiken L, Rege S, Hoh C, et al. Poistron Emission Tomography with fluorodeoxyglucose to evaluate tumor responce and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27: 455-64.
39. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993; 34: 12-7.
40. Haberkorn U, Strauss LG, Reisser C, et al. Poistron Emission Tomography (PET) in the evaluation of tumor proloferation and follow-up of therapy in ear, nose and throat tumors. Radiologe 1992; 32: 296-301.
41. Reisser C, Haberkorn U, Strauss-Dimitrakopoulou A, et al. Chemotherapeutic management of head and neck malignancies with Poistron Emission Tomography. Arch Otolaryngol Head Neck Surg 1995; 121: 272-6.
42. Dennington ML, Carter DR, Meyers AD. Distant metastases in head and neck epidermoid carcinoma. Laryngoscope 1980; 90: 196-201.
43. Calhoun KH, Fulmer P, Weiss R, et al. Distant metastases from head and neck squamous cell carcinomas. Laryngoscope 1994; 104: 1199-205.
44. Troell JT, Terris DJ. Detection of metastases from head and neck cancers. Laryngoscope 1994; 105: 247-50.